Toward Standardized Sequencing in Vitiligo Care

In "Toward Standardized Sequencing in Vitiligo Care," Dr. Lal and Jason debate whether vitiligo treatment sequencing can ever be standardized.

Dr. Lal welcomes the prospect of more treatment options but predicts individualized decision-making will persist even as clearer patterns emerge. He expects many clinicians to default to a straightforward rule: patients below a given body surface area threshold stay on topical therapy, while those above it move toward systemic treatment. Still, he cautions against dismissing topical therapy prematurely, since it currently outperforms oral therapy within comparable timeframes for patients who qualify for it. He remains uncertain what BSA threshold any approved oral JAK inhibitor label will ultimately specify, but suggests that even a defined cutoff would still leave meaningful room for individualized clinical judgment in borderline or complex cases.

Jason responds that meaningful standardization requires several building blocks still missing today. He points first to each therapy's eventual FDA label and Phase 3 results, cautioning that these cannot be compared head-to-head but will still shape policy interpretation. Real-world utilization patterns, including how well existing step therapy requirements perform in practice, provide additional signal for future coverage design. The most significant current gap, in his view, is the absence of established professional treatment guidelines specifically for vitiligo, since guidelines from specialty organizations are typically what payers lean on most heavily when constructing coverage policy. He acknowledges that such guidelines historically lag behind newly available therapies, which paradoxically helps payers manage near-term costs even though delayed guidance is not necessarily in patients' best clinical interest. He describes this tension as an inevitable, ongoing balancing act between innovation, evidence generation, and the practical realities of managing a health plan's finite resources across a growing patient population.

In the final episode, "Closing Reflections on the Future of Vitiligo Care," each panelist shares closing reflections on where vitiligo care is headed.